Advanced Search
CAO Mengran, HUA Haiqing, QIN Shukui. Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 387-390. DOI: 10.3971/j.issn.1000-8578.2014.04.023
Citation: CAO Mengran, HUA Haiqing, QIN Shukui. Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 387-390. DOI: 10.3971/j.issn.1000-8578.2014.04.023
shu

Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity

  • Department of Medical Oncology??Cancer Center of PLA,81 Hospital of PLA,Nanjing210002, China

More Information
  • Received Date: December 26, 2012
  • Revised Date: April 09, 2013
    Graphical Abstract
    • Abstract
  • Objective To observe the protective effects of monosialoganglioside on oxaliplatin-induced sensory neurotoxicity. Methods Sixty-eight patients receiving oxaliplatin-based chemotherapy were randomly divided into treatment group(n=38, monosialoganglioside, 40 mg/d, 3d) and control group(n=30, fursultiamine, 50 mg, orally bid, three times a day, continuous medication) to prevent oxaliplatin-induced sensory neurotoxicity. The acute and cumulative sensory neurotoxicity, chemotherapeutic effect and adverse reactions in two groups after chemotherapy were assessed. Results The incidence of acute sensory neurotoxicity in monosialoganglioside group was significantly lower than that in control group(5.3% vs. 26.7%, P=0.013). The incidence of cumulative sensory neurotoxicity in control group was 63.3%(19/30), with grade 1-2 in 15 cases, grade 3 in 3 cases and grade 4 in 1 case, signifi cantly higher than that 15.8%(6/38) in monosialoganglioside group, with grade 1-2 in 6 cases. There was no statistically signifi cant difference in chemotherapy-induced adverse reaction, ORR, DCR or mPFS between both groups. Conclusion Monosialoganglioside is an effective neuroprotectant against oxaliplatin-induced sensory neurotoxicity without infl uencing in chemotherapeutic effi cacy or chemotherapy-induced adverse reaction.
    • FullText(HTML)
    • References (10)
  • [1]
    Cassidy J, Misset JL.Oxaliplatin related side effects: Characteristics and management[J]. Semin Oncol, 2002, 29(5 Suppl 15):11-20.
    [2]
    Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer[J]. Cancer, 1992, 69(4):893-900.
    [3]
    Gamelin E,Gamelin L,Bassi L,et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures[J]. Semin Oncol, 2002, 29(5 Suppl 15):21-33.
    [4]
    Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy[J]. Muscle Nerce, 2004, 29(3):387-92.
    [5]
    Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of rat[J]. Eur J Cancer, 2001, 37(18):2457-63.
    [6]
    Cavaletti G, Petruccioli MG, Marmiroli P, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat[J].Anticancer Res, 2002,22(6C):4199-204.
    [7]
    De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological defi cits are characerized by a low circulating level of nerve growth factor[J]. Clin Cancer Res, 2000, 6( 1):90-5.
    [8]
    Hochster HS,Grothey A,Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity[J]. J Clin Oncol, 20 07, 25(25): 4028-9.
    [9]
    Yin XH, Sun LM, Deng SH. Mechanism of action and clinical research progress of monosialoganglioside[J].Zhongguo Ji Ceng Yi Yao,2006,13(9):1567-9.[尹晓慧, 孙立明, 邓树海. 神经节苷脂 作用机制及临床研究进展[J]. 中国基层医药,2006,13(9):1567-9.]
    [10]
    Ning N, Chen NH. Progress in the research of Ganglioside’ s biological activities[J]. Sheng Li Ke Xue Jin Zhan, 2009, 40 (1):24.[宁娜，陈乃宏. 神经节苷脂的生物学活性[J]. 生理科 学进展,2009,40(1):24.]
    • Related Articles

  • Related Articles

    [1]CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 438-443. DOI: 10.3971/j.issn.1000-8578.2022.21.1020
    [2]ZHANG Xiufen, LIU Beibei, GUO Zijian, LI Lihua. UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 743-747. DOI: 10.3971/j.issn.1000-8578.2016.09.003
    [3]XU Kai, CHENG Weiting, HU Zuowei, WANG Shan. Tanshinone ⅡA Inhibits Nerve Growth Factor Expression in Rats with Oxaliplatininduced Peripheral Neuropathy[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 648-651. DOI: 10.3971/j.issn.1000-8578.2015.07.002
    [4]ZHU Yan, WU Gang, OUYANG Lichen, ZHU Fang, CHE Jing, ZHOU Yi. Effects of Monosialoganglioside-3 on Apoptosis and VEGF Expression in Human Cervical Cancer Cell Line HeLa[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 450-453. DOI: 10.3971/j.issn.1000-8578.2015.05.006
    [5]SONG Min, MENG Yu, CHANG Zhiwei. Effects of Nav1.7 Expression on Neuropathic Pain Induced by Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 971-975. DOI: 10.3971/j.issn.1000-8578.2014.09.004
    [6]ZHU Yiping, SHENG Lili, WANG Lu, JI Zhaoning. Clinical Efficacy of Oxaliplatin Combined with Capecitabine(XELOX) and Oxaliplatin Combined with S-1 (SOX) on Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 815-819. DOI: 10.3971/j.issn.1000-8578.2014.07.028
    [7]QU Yanli, TANG Xushan, TANG Yong. Clinical Observation of S-1 Combined with Oxaliplatin or Paclitaxel on Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 811-814. DOI: 10.3971/j.issn.1000-8578.2014.07.027
    [8]YANG Lin, SONG Yan, QIN Qiong, DUAN Huijie, DONG Qian, ZHONG Xiaomin, ZHOU Aiping, HUANG Jing, WANG Jinwan. Efficacy and Safety of S-1 Combined with Oxaliplatin as First Line Chemotherapy in Patients with Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2013, 40(07): 688-692. DOI: 10.3971/j.issn.1000-8578.2013.07.013
    [9]SONG Min, MENG Yu, REN Xiuhua, CHANG Zhiwei, CHANG Jie, LI Lei. Effects and Mechanism of Venlafaxine on Neuropathic Pain Induced by Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2013, 40(06): 555-559. DOI: 10.3971/j.issn.1000-8578.2013.06.012
    [10]Zhao Yanxia, Cheng Jing, Zhu Fang, Wu Hongge, Chen Sheng. Study on Methylcobalamin in Preventing Docetaxel Chemotherapy-induced Peripheral Neurotoxicity in Patients with Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(12): 1487-1490. DOI: 10.3971/j.issn.1000-8578.2012.12.019

Catalog

    Get Citation
    PDF
    XML
    Article views (1384) PDF downloads (966) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：11642775 Visits today：10124

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return